News

The Study 116, a randomized, double-blind study, will enroll 160 patients to evaluate the utility of GS-1101 in combination with various chemoimmunotherapies in previously treated CLL patients. The

The two patents, owned by Aptalis and licensed to Cephalon, will expire in 2023 and 2025. Aptalis president John Fraher said, "Aptalis Pharmaceutical Technologies endeavors to offer to

The UPS 4 blister line provides primary packaging into a series of materials including PVC, PVC/PVDC, Aclar and Alu/Alu, by processing solid oral dose products. Almac manufacturing operations

The patent covers Inovio’s synthetic consensus HPV antigens, DNA constructs and vaccines that include these antigens, including VGX-3100, cervical dysplasia/cancer vaccine. The methods used for treating patients with

Bepotastine besilate is a non-sedating, antagonist of the histamine H1 receptor that acts by suppressing the migration of eosinophils into inflamed tissues. The Phase 2 randomised placebo-controlled parallel-group

As a part of the agreement, Gilead will receive antibodies produced by AnaptysBio by the means of SHM-XEL platform, for the development and commercialization. AnaptysBio president and chief

Under the collaboration, GSK integrates its expertise in medicinal chemistry with Yale’s work on proteolysis targeting chimeric molecules (PROTACs). The PROTAC technology directs disease-causing proteins to a cell’s

The grant will continue to support the research previously supported by a Phase I SBIR grant, the company said. With the grant, ImmuVen will continue development of its

The integrated cartridge system comprises necessary reagents to perform the assay and predict the presence of infection in the sample. The key benefits of the platform include, on-demand